Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $409.6 million.

  • Dexcom's Change in Acquisitions & Divestments rose 108.59% to $409.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.2 billion, marking a year-over-year decrease of 2335.72%. This contributed to the annual value of $2.2 billion for FY2025, which is 2335.72% down from last year.
  • As of Q4 2025, Dexcom's Change in Acquisitions & Divestments stood at $409.6 million, which was up 108.59% from $466.2 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Change in Acquisitions & Divestments ranged from a high of $1.1 billion in Q1 2024 and a low of $241.8 million during Q1 2022
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $644.4 million (2025), whereas its average is $636.5 million.
  • In the last 5 years, Dexcom's Change in Acquisitions & Divestments crashed by 6939.24% in 2022 and then soared by 18850.29% in 2023.
  • Dexcom's Change in Acquisitions & Divestments (Quarter) stood at $501.0 million in 2021, then skyrocketed by 47.7% to $740.0 million in 2022, then dropped by 2.84% to $719.0 million in 2023, then tumbled by 43.64% to $405.2 million in 2024, then grew by 1.09% to $409.6 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $409.6 million for Q4 2025, versus $466.2 million for Q3 2025 and $638.7 million for Q2 2025.